Myth or fact

ApoB is just another way to measure cholesterol

Short answerNo

By GyroscopeUpdated November 15, 20266 sources

No. ApoB is a protein, and one copy sits on every particle that can carry cholesterol into an artery wall, so the test counts those particles. LDL weighs the cholesterol inside them. In UK Biobank, people with the same LDL of 130 had ApoB levels anywhere from 86 to 109.

Why people believe it

ApoB shows up on the same lab report as your cholesterol, in the same units, and it rises and falls with LDL for most people. Its full name, apolipoprotein B, sounds like another kind of lipid, and in the loose sense that it comes on a cholesterol panel, it’s a cholesterol test.

But it measures a different thing. The 2026 US guideline says LDL “reflects the cholesterol mass within LDL particles rather than the number”, and ApoB “directly measures atherogenic particle number, with 1 molecule per LDL, very-low-density lipoprotein (VLDL), and Lp(a) particle”. Atherogenic means able to build plaque.

A headcount and a weigh-in

Picture a school bus. LDL tells you the total weight of the kids on board. ApoB tells you how many kids there are. For most buses the two track each other. A bus of small kids, though, can be light and packed at the same time. If you wanted to know how many seats are taken, you’d count heads. Your artery wall cares about the number of particles that try to get in, so ApoB is the headcount.

What the measurements show

In 2024, Sniderman and colleagues looked at 293,876 adults in UK Biobank aged 40 to 73, who between them had 19,982 new cases of heart disease or stroke over about 11 years. ApoB and LDL correlated at 0.96. That sounds like the same number, until you look at people with matching LDL. At an LDL of about 130, 95% of people had an ApoB between 86 and 109. The ones with a high ApoB for their LDL had nearly twice the 10-year rate of new heart disease and stroke as the ones with a low ApoB (7.3 against 4.0).

Two years earlier, a team led by Marston put ApoB, LDL, non-HDL and triglycerides in the same model for 429,959 people. Looked at one at a time, all of them were tied to heart attacks. Looked at together, “only apoB” was, in people with and without heart disease. They concluded the risk was “best captured by the number of apoB-containing lipoproteins”.

Why the count is what counts

Particles slip into the artery wall, and the National Lipid Association says ApoB’s strong electric charge helps trap them there. Each one that stays is the start of plaque. A particle with less cholesterol inside is still one particle, with one ApoB, and one chance to get stuck.

The gene research backs this up. In a 2019 study of 654,783 people, genes that lowered ApoB by 10 points cut the odds of heart disease by about 23%, whether they did it by lowering triglycerides or LDL. The cargo was different, and the count gave the same result.

The best case for the myth

A skeptic can point to that 0.96 and say that for most people a second test adds nothing, and for most people that’s true. If your triglycerides are normal, you don’t have diabetes, and your LDL was worked out with a modern formula, your ApoB will usually tell the same story. The 2026 guideline says that with the newer Martin/Hopkins method, only about 2% of people with an LDL under 70 had an ApoB over the goal.

ApoB earns its place in the people where the two split, who tend to be the people at more risk. That’s why we’d ask for it anyway. It’s the same blood draw, and the test costs little to run.